Advertisement

Midterm Mortality between Single or Multiple Exposure to Paclitaxel Coated Devices for the Treatment of Femoropopliteal Artery Disease

  • Author Footnotes
    ‡ Drs Kuan-Liang Liu and I-Shiang Tzeng contributed equally to this work.
    Kuan-Liang Liu
    Footnotes
    ‡ Drs Kuan-Liang Liu and I-Shiang Tzeng contributed equally to this work.
    Affiliations
    Division of Cardiology, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan
    Search for articles by this author
  • Author Footnotes
    ‡ Drs Kuan-Liang Liu and I-Shiang Tzeng contributed equally to this work.
    I-Shiang Tzeng
    Footnotes
    ‡ Drs Kuan-Liang Liu and I-Shiang Tzeng contributed equally to this work.
    Affiliations
    Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan
    Search for articles by this author
  • I-Chih Chen
    Affiliations
    Division of Cardiology, Tainan Municipal Hospital, Tainan, Taiwan
    Search for articles by this author
  • Shih-Jung Jang
    Affiliations
    Division of Cardiology, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

    School of Medicine, Tzu Chi University, Hualien, Taiwan
    Search for articles by this author
  • Hsin-Hua Chou
    Affiliations
    Division of Cardiology, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

    School of Medicine, Tzu Chi University, Hualien, Taiwan
    Search for articles by this author
  • Hsuan-Li Huang
    Correspondence
    Corresponding author. Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 289 Jiang Kuo Road, Xindian District, New Taipei City 231, Taiwan.
    Affiliations
    Division of Cardiology, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

    School of Post-baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan
    Search for articles by this author
  • Author Footnotes
    ‡ Drs Kuan-Liang Liu and I-Shiang Tzeng contributed equally to this work.
Published:November 23, 2021DOI:https://doi.org/10.1016/j.ejvs.2021.09.027
      A recent meta-analysis reported late excess mortality in patients treated with paclitaxel coated devices (PCDs) for symptomatic femoropopliteal disease.
      • Katsanos K.
      • Spiliopoulos S.
      • Kitrou P.
      • Krokidis M.
      • Karnabatidis D.
      Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials.
      However, this statement is the subject of debate, and subsequent studies showed no mortality difference
      • Nordanstig J.
      • James S.
      • Andersson M.
      • Andersson M.
      • Danielsson P.
      • Gillgren P.
      • et al.
      Mortality with paclitaxel-coated devices in peripheral artery disease.
      ,
      • Secemsky E.A.
      • Shen C.
      • Schermerhorn M.
      • Yeh R.W.
      Longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries: the SAFE-PAD study.
      or improved survival in PCD treatment groups in a large cohort observation.
      • Behrendt C.A.
      • Sedrakyan A.
      • Peters F.
      • Kreutzburg T.
      • Schermerhorn M.
      • Bertges D.J.
      • et al.
      Editor's Choice – long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis.
      The cumulative effect of repeated exposure to paclitaxel remains uncertain. This study aimed to investigate the mortality impact regarding repeated PCDs in femoropopliteal intervention.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Katsanos K.
        • Spiliopoulos S.
        • Kitrou P.
        • Krokidis M.
        • Karnabatidis D.
        Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials.
        J Am Heart Assoc. 2018; 7e011245
        • Nordanstig J.
        • James S.
        • Andersson M.
        • Andersson M.
        • Danielsson P.
        • Gillgren P.
        • et al.
        Mortality with paclitaxel-coated devices in peripheral artery disease.
        N Engl J Med. 2020; 383: 2538-2546
        • Secemsky E.A.
        • Shen C.
        • Schermerhorn M.
        • Yeh R.W.
        Longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries: the SAFE-PAD study.
        JAMA Intern Med. 2021; 181: 1071-1080
        • Behrendt C.A.
        • Sedrakyan A.
        • Peters F.
        • Kreutzburg T.
        • Schermerhorn M.
        • Bertges D.J.
        • et al.
        Editor's Choice – long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis.
        Eur J Vasc Endovasc Surg. 2020; 59: 587-596
        • Von Allmen R.S.
        • Weiss S.
        • Tevaearai H.T.
        • Kuemmerli C.
        • Tinner C.
        • Carrel T.P.
        • et al.
        Completeness of follow-up determines validity of study findings: results of a prospective repeated measures cohort study.
        PLoS One. 2015; 10e0140817
        • Keller K.
        • Hobohm L.
        • Geyer M.
        • Münzel T.
        • Lavie C.J.
        • Ostad M.A.
        • et al.
        Obesity paradox in peripheral artery disease.
        Clin Nutr. 2019; 38: 2269-2276